5.1. Study Design
TMD, arthrogenous disorder, myalgia
TMJ
A double-blind, randomized, controlled clinical trial was conducted between January 2021 and December 2021. This study was approved by the Ethics Committee of the Portuguese Institute of the Face (PT/IPFace/RCT/0121/07). The study was registered in ClinicalTrials.Gov (NCT04810429). All the patients signed the informed consent in accordance with the current legislation and the guidelines of the Declaration of Helsinki.Patients of both genders with TMD diagnosis and indication for bilateral TMJ arthroscopy were recruited. The inclusion criteria included: (1) Age of 18–60 years; (2) history of conservative treatment for TMD without significant improvement for at least three months; (3) clinical diagnosis of bilateral arthrogenous disorder; (4) clinical diagnosis of myalgia; (5) clinical criteria for bilateral TMJ arthroscopy (Dimitroulis Classification 2–4) [